ARID1A | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

156 results for “ARID1A”

Trials

View all 93 →

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

30 participants · First posted Feb 25, 2020

Not yet recruiting

TR115 in ARID1A-Mutated Advanced Solid Tumors

50 participants · First posted Aug 28, 2026

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

25 participants · First posted Jul 24, 2024

Drugs

View all 15 →

Selective ARID1B(Foghorn Therapeutics)

JARID1A/1B inhibitors (Celgene)

ARINA-1

Organizations

View all 12 →

Arpida AG

Switzerland

Aridis Pharmaceuticals, Inc.

United States

Atridia Pty Ltd.

Australia

News

View all 36 →

NXP800 Receives FDA Orphan Drug Designation for ARID1a-Deficient Ovarian Cancers

Nuvectis Pharma's NXP800 Shows Promise in ARID1a-Mutated Ovarian Cancer Trial

Nuvectis Pharma Reports Financial Results and Highlights Clinical Progress of NXP800 and NXP900

Page 1 of 16